Athena Athena

X
[{"orgOrder":0,"company":"ArQule","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of ArQule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by ArQule

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ArQule became a wholly owned subsidiary of Merck upon completion of the acquisition.

            Lead Product(s): ARQ 531

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: $2,700.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition January 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY